SQM Reports Earnings For The Second Quarter 2014
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
The U.S. economy is in decent shape, but we are being even more selective given recent outperformance.
As macro headwinds mount, we would look for a larger valuation discount among consumer cyclical names.
As the risk of increasing inflation looms, the risk/reward opportunity in stocks does not signal a screaming buy to us at this point.